Michael J. Yang - 01 Jul 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 01 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2025, 16:53:41 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 17 Jul 2025
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Michael J. Yang

Key filing fact

Michael J. Yang filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 02 Jul 2025.

Key facts

This page summarizes Michael J. Yang's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jul 2025, 16:53.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001702283 Primary reporting owner

YANG MICHAEL J.

Relationship: Director
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Michael J. Yang
Signature date: 02 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +11,518
Change %
Price: $0.000000
Shares after: 11,518
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,518
Exercise price: $39.94
Footnotes: F1, F2

IONS transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +5,220
Change %: +66%
Price: $0.000000
Shares after: 13,159
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,220
Exercise price: $0.000000
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

Footnote F2

Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

Footnote F3

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F4

Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.